Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116551 · ClinicalTrials.gov registry record · NA
Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis
A NA study of Symptomatic Severe Aortic Stenosis, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 5
- Study locations
NCT07116551: Active NA study of Symptomatic Severe Aortic Stenosis, sponsored by Abbott Medical Devices.
NCT07116551 is a NA study of Symptomatic Severe Aortic Stenosis that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116551, a NA study of Symptomatic Severe Aortic Stenosis, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and functionality of Abbott's BE TAVI system for the treatment of patients with symptomatic severe aortic valve stenosis.
Primary Outcome
Successful access, delivery of the Abbott BE TAVI valve, and retrieval of the delivery system.
Conditions Studied
Interventions
- DEVICE Abbott BE TAVI System
Study Locations (5)
New York
- Columbia University Medical Center/New York-Presbyterian - New York
- Montefiore Medical Center - Moses Division - The Bronx
Kansas
- Via Christi Regional Medical Center - Wichita
Minnesota
- Abbott Northwestern Hospital - Minneapolis
Midpyre
- Clinique Pasteur Toulouse - Toulouse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2031-06 |
| Phase | NA |
What the registry record for NCT07116551 still lists
NCT07116551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Symptomatic Severe Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which Abbott BE TAVI System is the first listed.
NCT07116551 lists 5 locations in 4 states (New York, Kansas, Minnesota).
Frequently Asked Questions
What is clinical trial NCT07116551 about?
NCT07116551 is a clinical study titled "Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis". The purpose of this study is to evaluate the safety and functionality of Abbott's BE TAVI system for the treatment of patients with symptomatic severe aortic valve stenosis.
What is the current status of trial NCT07116551?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 11 participants. The study started on 2025-10-30. Estimated completion is 2031-06.
What conditions does trial NCT07116551 study?
This clinical trial studies the following conditions: Symptomatic Severe Aortic Stenosis.
What interventions are being tested in trial NCT07116551?
The interventions under investigation include: Abbott BE TAVI System (DEVICE).
Who is sponsoring clinical trial NCT07116551?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116551 being conducted?
This trial has 5 study locations across Kansas, Minnesota, New York, Midpyre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Symptomatic Severe Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07116551's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI